{"id":"https://openalex.org/W3094072094","doi":"https://doi.org/10.1136/annrheumdis-2019-216835","title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","display_name":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","alternate_titles":[],"publication_year":2020,"publication_date":"2020-10-26","ids":{"openalex":"https://openalex.org/W3094072094","doi":"https://doi.org/10.1136/annrheumdis-2019-216835","mag":"3094072094","pmid":"https://pubmed.ncbi.nlm.nih.gov/33106286","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7815636"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2019-216835","doi":"https://doi.org/10.1136/annrheumdis-2019-216835","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2019-216835","pdf_url":"https://ard.bmj.com/content/annrheumdis/80/2/185.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3094072094"],"child_works_count":3,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://ard.bmj.com/content/annrheumdis/80/2/185.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081778211","display_name":"Philip J. Mease","orcid":"https://orcid.org/0000-0002-6620-0457","observed_orcids":["https://orcid.org/0000-0002-6620-0457"]},"institutions":[{"id":"https://openalex.org/I4210093417","display_name":"Swedish Medical Center","ror":"https://ror.org/004jktf35","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210093417","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Philip J Mease","raw_affiliation_strings":["Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA pmease@philipmease.com","Rheumatology Research, Swedish Medical Center, Seattle, WA 98122, USA"],"raw_orcid":"https://orcid.org/0000-0002-6620-0457","affiliations":[{"raw_affiliation_string":"Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA pmease@philipmease.com","institution_ids":["https://openalex.org/I4210093417"]},{"raw_affiliation_string":"Rheumatology Research, Swedish Medical Center, Seattle, WA 98122, USA","institution_ids":["https://openalex.org/I4210093417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051239558","display_name":"Philip Helliwell","orcid":"https://orcid.org/0000-0002-4155-9105","observed_orcids":["https://orcid.org/0000-0002-4155-9105"]},"institutions":[{"id":"https://openalex.org/I130828816","display_name":"University of Leeds","ror":"https://ror.org/024mrxd33","country_code":"GB","type":"education","lineage":["https://openalex.org/I130828816"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Philip S Helliwell","raw_affiliation_strings":["Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK","institution_ids":["https://openalex.org/I130828816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083403778","display_name":"Kasper Fjellhaugen Hjuler","orcid":"https://orcid.org/0000-0001-6082-5096","observed_orcids":["https://orcid.org/0000-0001-6082-5096"]},"institutions":[{"id":"https://openalex.org/I2802335433","display_name":"Aarhus University Hospital","ror":"https://ror.org/040r8fr65","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802335433"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kasper Fjellhaugen Hjuler","raw_affiliation_strings":["Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"],"raw_orcid":"https://orcid.org/0000-0001-6082-5096","affiliations":[{"raw_affiliation_string":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark","institution_ids":["https://openalex.org/I2802335433"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113841619","display_name":"Kyle Raymond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165112","display_name":"Leo Pharma (Denmark)","ror":"https://ror.org/05tzrdd39","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210124980","https://openalex.org/I4210165112"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kyle Raymond","raw_affiliation_strings":["Medical Department, Leo Pharma, Ballerup, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Department, Leo Pharma, Ballerup, Denmark","institution_ids":["https://openalex.org/I4210165112"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071482630","display_name":"Iain B. McInnes","orcid":"https://orcid.org/0000-0002-6462-4280","observed_orcids":["https://orcid.org/0000-0002-6462-4280","https://orcid.org/0000-0003-4449-8501"]},"institutions":[{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Iain McInnes","raw_affiliation_strings":["Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK","institution_ids":["https://openalex.org/I7882870"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5081778211"],"corresponding_institution_ids":["https://openalex.org/I4210093417"],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":{"value":4870,"currency":"USD","value_usd":4870},"fwci":12.5541,"has_fulltext":true,"cited_by_count":139,"citation_normalized_percentile":{"value":0.99355478,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":100},"biblio":{"volume":"80","issue":"2","first_page":"185","last_page":"193"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brodalumab","display_name":"brodalumab","score":1.0},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/acr20-response","display_name":"ACR20 response","score":0.8209999799728394},{"id":"https://openalex.org/keywords/dactylitis","display_name":"dactylitis","score":0.765999972820282},{"id":"https://openalex.org/keywords/enthesitis","display_name":"enthesitis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.4779999852180481},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5759999752044678},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.527999997138977}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9669681191444397},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.832732081413269},{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.4916422963142395},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.4841797649860382},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.45618003606796265},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.41804251074790955},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3774165213108063},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.12778180837631226}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015535","descriptor_name":"Arthritis, Psoriatic","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053722","descriptor_name":"Receptors, Interleukin-17","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1136/annrheumdis-2019-216835","doi":"https://doi.org/10.1136/annrheumdis-2019-216835","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2019-216835","pdf_url":"https://ard.bmj.com/content/annrheumdis/80/2/185.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:openaire/a26b37c5-eafa-4480-bd3b-63acccddc22f","doi":null,"is_oa":true,"landing_page_url":"https://pure.au.dk/portal/en/publications/a26b37c5-eafa-4480-bd3b-63acccddc22f","pdf_url":"https://pure.au.dk/ws/files/273930576/185.full.pdf","source":null,"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Mease, P J, Helliwell, P S, Hjuler, K F, Raymond, K & Mcinnes, I 2021, 'Brodalumab in psoriatic arthritis : results from the randomised phase III AMVISION-1 and AMVISION-2 trials', Annals of the Rheumatic Diseases, vol. 80, no. 2, pp. 185-193. https://doi.org/10.1136/annrheumdis-2019-216835","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7815636","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7815636/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ann Rheum Dis","raw_type":"Text"},{"id":"pmid:33106286","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33106286","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the rheumatic diseases","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:eprints.gla.ac.uk:231546","doi":null,"is_oa":false,"landing_page_url":"https://eprints.gla.ac.uk/231546/1/231546.pdf","pdf_url":"https://eprints.gla.ac.uk/231546/1/231546.pdf","source":{"id":"https://openalex.org/S7407122635","display_name":"Enlighten: Publications (University of Glasgow)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I7882870","host_organization_name":"University of Glasgow","host_organization_lineage":["https://openalex.org/I7882870"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Articles"}],"best_oa_location":{"id":"doi:10.1136/annrheumdis-2019-216835","doi":"https://doi.org/10.1136/annrheumdis-2019-216835","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2019-216835","pdf_url":"https://ard.bmj.com/content/annrheumdis/80/2/185.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320332071","display_name":"LEO Pharma","ror":"https://ror.org/05tzrdd39"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3094072094.pdf","grobid_xml":"https://content.openalex.org/works/W3094072094.grobid-xml"},"referenced_works_count":35,"referenced_works":["https://openalex.org/W1777824885","https://openalex.org/W1935617463","https://openalex.org/W1948195609","https://openalex.org/W2019678439","https://openalex.org/W2022466169","https://openalex.org/W2050604953","https://openalex.org/W2050706371","https://openalex.org/W2053127888","https://openalex.org/W2060527543","https://openalex.org/W2061205096","https://openalex.org/W2068614670","https://openalex.org/W2083180635","https://openalex.org/W2088569180","https://openalex.org/W2103524303","https://openalex.org/W2107553722","https://openalex.org/W2108984264","https://openalex.org/W2121900420","https://openalex.org/W2137101132","https://openalex.org/W2139788459","https://openalex.org/W2145778588","https://openalex.org/W2145834141","https://openalex.org/W2194197257","https://openalex.org/W2195521042","https://openalex.org/W2223868808","https://openalex.org/W2256155471","https://openalex.org/W2276035339","https://openalex.org/W2326643498","https://openalex.org/W2588887926","https://openalex.org/W2770001657","https://openalex.org/W2883191655","https://openalex.org/W2887422108","https://openalex.org/W2951819520","https://openalex.org/W2953889774","https://openalex.org/W4211046919","https://openalex.org/W4234517985"],"related_works":["https://openalex.org/W2053127888","https://openalex.org/W2319342693","https://openalex.org/W3164689273","https://openalex.org/W2334337629","https://openalex.org/W2337006501","https://openalex.org/W2100107304","https://openalex.org/W2625170996","https://openalex.org/W7160235659","https://openalex.org/W4248566592","https://openalex.org/W2276035339"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"compare":[2],"the":[3,90,107],"efficacy":[4],"and":[5,29,46,48,66,129,152,157,183,187,191,208,215,231,236],"safety":[6,221,248],"of":[7,76,81,93,175,189,238],"brodalumab,":[8],"an":[9],"interleukin-17":[10,253],"receptor":[11],"subunit":[12],"A":[13],"inhibitor,":[14],"with":[15,19,26,229,246,251],"placebo,":[16,211],"in":[17,122,146,234],"patients":[18,25,77,103,140,176],"psoriatic":[20],"arthritis":[21],"(PsA).":[22],"METHODS:":[23],"Adult":[24],"active":[27],"PsA":[28,239],"inadequate":[30],"response":[31,97],"to,":[32,35],"or":[33,57,60],"intolerance":[34],"conventional":[36],"treatment":[37,149],"were":[38,104,136,167,199,223],"enrolled":[39],"into":[40],"two":[41],"phase":[42],"III":[43],"studies":[44,88,108,135],"(NCT02029495":[45],"NCT02024646)":[47],"randomised":[49,105],"1:1:1":[50],"to":[51,71,110,114],"receive":[52],"subcutaneous":[53],"brodalumab":[54,148,178,212],"140":[55,155,213],"mg":[56,59,156,214],"210":[58,158,216],"placebo":[61,162,194],"at":[62,98,143,169,203],"weeks":[63,69],"0,":[64],"1":[65],"every":[67],"2":[68],"up":[70],"24":[72],"weeks.":[73],"About":[74],"30%":[75],"had":[78],"prior":[79,109],"use":[80],"biologics.":[82],"The":[83,117],"primary":[84,118],"endpoint":[85,119],"for":[86,154,210],"both":[87,123,134,147],"was":[89,120,227,243],"American":[91],"College":[92],"Rheumatology":[94],"20":[95],"(ACR20)":[96],"week":[99,144,170,204],"16.":[100],"RESULTS:":[101],"962":[102],"across":[106,201],"early":[111],"termination":[112],"due":[113],"sponsor":[115],"decision.":[116],"met":[121],"studies.":[124],"Based":[125],"on":[126],"comparable":[127],"design":[128],"eligibility":[130],"criteria,":[131],"data":[132],"from":[133],"pooled.":[137],"Significantly":[138,172],"more":[139],"achieved":[141,179],"ACR20":[142],"16":[145,205],"groups":[150],"(45.8%":[151],"47.9%":[153],"mg,":[159,217],"respectively)":[160],"versus":[161,193,240],"(20.9%)":[163],"(p<0.0001).":[164],"Similar":[165],"results":[166],"observed":[168],"24.":[171],"higher":[173],"proportions":[174],"receiving":[177],"ACR50/70,":[180],"Psoriasis":[181],"Area":[182],"Severity":[184],"Index":[185],"75/90/100":[186],"resolution":[188],"dactylitis":[190],"enthesitis":[192],"(p<0.01).":[195],"Adverse":[196],"event":[197],"rates":[198],"similar":[200],"treatments":[202],"(54.4%,":[206],"51.6%":[207],"54.5%":[209],"respectively).":[218],"No":[219],"new":[220],"signals":[222],"reported.":[224],"CONCLUSION:":[225],"Brodalumab":[226,242],"associated":[228],"rapid":[230],"significant":[232],"improvements":[233],"signs":[235],"symptoms":[237],"placebo.":[241],"well":[244],"tolerated,":[245],"a":[247],"profile":[249],"consistent":[250],"other":[252],"inhibitors.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3094072094","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":27},{"year":2024,"cited_by_count":19},{"year":2023,"cited_by_count":37},{"year":2022,"cited_by_count":27},{"year":2021,"cited_by_count":22},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2020-10-29T00:00:00"}
